Tumors displaying loss of an MMR protein can be collectively referred to as MMR deficiency and are considered to be MSI-H, whereas those with intact MMR proteins are expected to be MSS or MSI-low [6, 8, 16]. Here, MRC1 is linked to mismatch repair cancer syndrome 1.